Maximilian J Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C Puhr, Angelika M Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W Prager, Wolfgang W Lamm, Anna S Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer
BACKGROUND: Patients with cancer are at high risk for severe courses of COVID-19. Based on (pre-)clinical data suggesting a potential protective effect due to the immunomodulating properties of azithromycin, we have initiated a prospective randomized trial. METHODS: This randomized, single-center, single-blinded, placebo-controlled phase 2 trial included adult patients with cancer undergoing systemic treatment. Patients were 1:1 randomized to oral azithromycin (1500 mg once weekly for 8 weeks) or placebo...
February 12, 2023: Infectious Agents and Cancer